News

Find News

Filter articles

Applied Filters

Showing 111 to 120 of 910 results

Pharma industry challenges Canada’s drug pricing plan

Canada09-09-2019Sarah Morgan

Innovative Medicines Canada, an association that represents drugmakers in Canada, has challenged the overhaul of Canada’s drug-pricing regime.

Federal Circuit blocks Sandoz generic

US30-08-2019Rory O'Neill

The US Court of Appeals for the Federal Circuit has ruled that claims in an Allergan patent detailing the results of a glaucoma treatment are material to its patentability, after an unsuccessful invalidation appeal brought by Sandoz.

Delhi court approves Natco generic of Novartis cancer drug

Asia, India29-08-2019Rory O'Neill

The Delhi High Court has cleared the way for a generic version of Novartis’ small-cell lung cancer drug Ceritinib, after the Swiss pharmaceutical company’s patent was revoked.

PTAB institutes IPR of Nalox-1 opioid overdose treatment

US29-08-2019Saman Javed

The US Patent Trial and Appeal Board has instituted an inter partes review into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.

Takeda subsidiary ordered to pay Bayer $182m after overturn bid fails

US27-08-2019Saman Javed

A Takeda subsidiary cannot overturn a $155 million jury verdict that it infringed one of Bayer’s patents, a district court has ruled.

Gilead challenges US govt patents on HIV drug Truvada

US22-08-2019

Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug. 

Novo Nordisk seeks to block Mylan generic

US22-08-2019Rory O'Neill

Danish pharmaceutical company Novo Nordisk has sued Mylan in a US court over a proposed generic of diabetes drug Victoza (liraglutide).

Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug

US20-08-2019Sarah Morgan

Amneal and three other generic makers have agreed to pay $1.54 million to settle a class-action lawsuit, which alleged the companies engaged in an unlawful scheme to maintain their monopoly over an Alzheimer’s drug.

Fed Circuit majority ‘problematically’ adds new rule in Actavis suit: chief judge

US16-08-2019

The US Court of Appeals for the Federal Circuit yesterday, August 15, blocked Actavis’s attempt to market a generic version of Nalpropion Pharmaceuticals’ weight-loss drug Contrave.

Sanofi victorious at Fed Circ in prostate cancer drug dispute

15-08-2019Sarah Morgan

Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.

Showing 111 to 120 of 910 results

LSIPR